Intelligent Bio Solutions clears interference study, stays on course for FDA 510(k) submission in H2 2026
INBS sits 20% above its 52-week low of $1.52 on light trading volume (0.3× avg).
Summary
Intelligent Bio Solutions has completed its Interference Study for the fingerprint drug screening system, a pivotal step toward FDA 510(k) clearance. The company remains on track to file its application in the second half of 2026.
Key Events · Product Development and Regulatory · INBS
-
Interference Study Completed
The study assessed whether everyday substances—hand creams, oils, dirt—affect the fingerprint drug screening system's accuracy. Its completion bolsters the FDA 510(k) submission for codeine detection.
-
Regulatory Milestone Achieved
This study is one component of a broader program that includes a Cut-off Study, Method Comparison Study, precision testing, and penetration testing—all necessary for FDA clearance.
-
510(k) Submission Timeline Maintained
The company remains on track to submit its 510(k) package in calendar H2 2026, targeting entry into the U.S. drug screening market.
-
Data Analysis Underway
Results are undergoing independent verification via liquid chromatography-tandem mass spectrometry (LC-MS/MS), a rigorous analytical method.
Analysis · INBS · Industrial Applications And Services
Completing the Interference Study removes a major hurdle on the path to FDA 510(k) submission. It satisfies a critical regulatory demand—proving that common contaminants do not compromise test accuracy—and keeps the company on schedule to enter the multi-billion-dollar U.S. drug screening market. With going-concern warnings and material weaknesses in the background, this milestone underscores the core technology's viability and the route to potential commercialization.
At the time of this filing, INBS was trading at $1.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.